Real-world data registry aims to bridge the evidence gap in multiple sclerosis research
The Corrona Multiple Sclerosis (MS) Registry, the sixth registry created by Corrona LLC, was established in 2017, in collaboration with the National MS Society, with the purpose of studying the real-world effectiveness and safety of approved therapies for MS.
The registry collects clinical data prospectively from both MS patients and their treating neurologists and then shares the data with clinical and research communities through journals and poster presentations at scientific conferences. So far, over 700 patients are enrolled in the project.
In addition to collaborating with pharmaceutical companies, Corrona also sponsors academic research across all the registries.
Executive VP of Research at the National MS Society, Bruce Bebo said the MS registry will “provide the real-world context needed to make informed treatment decisions.”
According to Aaron Miller, Scientific Co-Director at the registry, reviewing data from the registry can, “provide valuable insight into the impact of treatments on clinical outcomes and quality of life for MS patients.”
The other registries created by Corrona are: The Rheumatoid Arthritis Registry, the Psoriasis Registry, the Psoriatic Arthritis and Spondyloarthritis Registry, the Inflammatory Bowel Disease Registry, the CERTAIN Rheumatoid Arthritis Registry and the Japan RA Registry.
Corrona’s registries collaborate with over 400 participating investigator sites, while the data have been used in over 140 per reviewed manuscripts and 430 abstracts.
The company has conducted active safety surveillance to support regulatory commitments for 14 new drug approvals, including formal post authorization safety studies.
